Symptomatic and asymptomatic long-term recurrences following transcatheter atrial fibrillation ablation

Sabrina Manganiello, Matteo Anselmino, Claudia Amellone, Elisa Pelissero, Marco Giuggia, Giuseppe Trapani, Benedetta Giordano, Gaetano Senatore, Fiorenzo Gaita, Sabrina Manganiello, Matteo Anselmino, Claudia Amellone, Elisa Pelissero, Marco Giuggia, Giuseppe Trapani, Benedetta Giordano, Gaetano Senatore, Fiorenzo Gaita

Abstract

Background: Atrial fibrillation (AF) relapses, following transcatheter AF ablation, are frequently reported based on patients' symptoms, scheduled electrocardiograms (ECGs), or 24-hour Holter recordings. The aim of this study is to determine the incidence of asymptomatic and symptomatic AF recurrences, using continuous subcutaneous ECG monitoring, in the long-term follow-up of patients with paroxysmal or persistent AF undergoing transcatheter ablation.

Methods and results: In total 113 consecutive patients symptomatic for paroxysmal or persistent AF were enrolled. All patients underwent pulmonary vein isolation plus left linear lesions. The insertable cardiac monitor (ICM), subcutaneously implanted during the ablation procedure, recorded the amount of AF per day (daily burden) and per last follow-up period (total AF burden). Based on symptoms and on scheduled 12-lead ECG performed during follow-up, 40 patients (35.4%) suffered AF recurrences. By means of ICM data, however, arrhythmia relapses were recorded within 75 patients (66.3%), of whom 35 (46.7%) were asymptomatic. Patients suffering symptomatic AF recurrences resulted, at univariate analysis, older (66.6 ± 8.4 years vs 61.6 ± 10.7 years) and suffering greater AF burden (88.8 ± 26.9% vs 8.0 ± 8.0%).

Conclusions: AF ablation outcome based on patients' symptoms and/or scheduled ECGs underestimated relapses, as up to half of the patients, during a long-term follow-up, suffer asymptomatic recurrences.

Keywords: asymptomatic recurrences; paroxysmal and persistent atrial fibrillation; transcatheter ablation.

©2014 Wiley Periodicals, Inc.

Source: PubMed

3
Prenumerera